Breaking News on Drug Discovery |
All news articles > December 2006
| « Previous month | Next month » |
20-Dec-2006
A possible cure for diabetes
A breakthrough in diabetes research has finally let scientists answer the elusive question of what causes the disease, enabling them to develop to a new treatment that reverses its effects.
How polo kinases split cells
Scientists have discovered how a key enzyme involved in cell division works, which could lead to more effective cancer treatments.
GSK sign world's-biggest licensing deal with Genmab
GlaxoSmithKline (GSK) has broken an industry record by licensing a drug for leukaemia from Genmab for $2.1bn (€1.6bn).
Fluidigm develops digital PCR technology
Fluidigm has launched its digital PCR technology, allowing scientists to analyse a single DNA template, which will give them the opportunity to detect cancer much earlier.
Bridge expand capabilities by acquiring Gene Logic unit
Bridge Pharmaceuticals has expanded its pre-clinical drug evaluation capabilities with the purchase of a division of Gene Logic for $15m
18-Dec-2006
Antisense drugs stop making sense?
The once hyped antisense sector of the pharmaceutical industry has again proved a disappointment after one drug in development was refused approval and another was scrapped.
Evolving enzymes - increasing efficiency for drug makers
The directed evolution of enzymes can lead to more efficient tools for the synthesis of drug molecules.
PACS stem cell purifier
New stem cell purification technology allows fast and accurate purification.
MDS lose C$10m to FDA review in Q4
MDS has been heavily impacted by a US Food and Drug Administration procedural review of its bioanalytical operations, but still managed to report quarterly earnings of C$53m (€35m).
15-Dec-2006
Genentech begins Alzheimer's Research
Genentech has decided to take an expensive short cut into the world of Alzheimer's research.
Patients don't care about conflicts of interest
Most cancer patients participating in clinical trials only care about their health, not whether researchers have financial interests in its outcome.
AQIX liquid preserves tissue life and function
Synthetic extra-cellular fluid maintains cell function and life while increasing pre-clinical trial reproducibility.
Next generation anti blood clot drug on the way
The race to find the next generation of treatments that prevent the formation of potentially fatal blood clots heated up when Boehringer Ingelheim announced positive Phase III trial results.
The changing face of allergy therapeutics
Oral immuno-therapies offer a cure, rather than just relief, to millions of hayfever sufferers worldwide.
14-Dec-2006
FDA seeks wider access to experimental drugs
Seriously ill patients in the US could soon have greater access to experimental drugs if a planned regulatory overhaul by the Food and Drug Administration (FDA) goes ahead.
13-Dec-2006
UK drug development needs new path
According to a review of public healthcare funding, the current method of developing drugs is unsustainable and must be updated if the UK is to remain at the forefront of European bioscience.
Merck bids for cholesterol market leadership
Merck will file for approval of a promising new cholesterol-lowerting drug in a bid to wrestle control of the cholesterol market away from Pfizer.
GSK to partner EPIX in search for potential Alzheimer's treatments
Sufferers of Alzheimer's have received a boost with the news that GlaxoSmithKine has ploughed further investment into developing new drugs to combat the disease.
Three strikes for Bayer as alfimeprase trials fail
Three failed clinical trials on two different drug candidates in a week are bad enough for Bayer but it is their collaborators who are really suffering.
Primate research backed by UK experts
British scientists have supported the use of primates in medical research, but only if no alternatives are available.
12-Dec-2006
Xceleron to expand capabilities after 2m (3m) investment
Xceleron have received a further £2m (€3m) investment to fund expansion of its core US and UK microdose markets.
11-Dec-2006
Biophage to release novel biosensor
Biophage will soon release its PDS96 Biosensor, allowing fast and highly cost-efficient early stage pre-clinical screening of drug candidates.
R&D tax credits passed by US House
US drug development sector receives a $16bn (€12bn) boost as the lower House votes to renew the tax credit system.
Federal scientist pleads guilty
A leading Alzheimer's expert has pleaded guilty to a conflict of interest charge relating to money he received from a pharmaceutical company while conducting research for the US government.
Stroke symptoms reversed by stem cell therapy?
People who have been left disabled from a stroke could have their symptoms reversed if a new stem cell therapy proves effective.
08-Dec-2006
GSK invests in miniature antibodies
GlaxoSmithKline is adding to its investments in biopharmaceutical drug development through the acquisition of pioneering mini-antibody technology.
GM bacteria eats cancer
A genetically modified bacterium has been found to eat tumours and secrete a protein that opens up 'packaged' anti-cancer therapies.
Duff reports on clinical trial safety
Experts have made 22 recommendations to improve the safety of Phase I drug trials after the disastrous trial that nearly killed six volunteers.
Onyx fall away in race to find skin cancer drug
Onyx Pharmaceuticals have fallen out of the race to find a badly needed new treatment for skin cancer after their lead drug tripped up in its final stage clinical trial.
07-Dec-2006
Galapagos buys into improved drug discovery
Galapagos is to spend up to €19.1m to acquire Inpharmatica in order to accelerate their drug discovery capabilities, especially in the early stages of development.
06-Dec-2006
Alta purchase takes Intertek into bioanalysis market
Intertek has broadened its portfolio to offer outsourced analysis of biologics as well as small molecules by purchasing Alta Laboratories, for $25m (€18.8m).
Nanomechanical devices detect disease
The dream of personalised medicine has taken another step towards reality as scientists have developed an innovative nanomechanical sensor for detecting disease and observing the body's reaction to treatment.
Federal scientist faces prison over conflict of interest charge
A federal scientist has been charged with criminal conflict of interest after he allegedly performed consultancy work that improperly overlapped with government work.
Viagra faces stiff competition from gene therapy
A more spontaneous future for sufferers of erectile dysfunction has been heralded by the successful completion of a Phase I clinical trial of a new gene therapy which could provide six months' effect with a single dose.
04-Dec-2006
Lipidome-based therapies could signal the end for cancer growth
Lipid-binding antibodies that block the interaction between cancerous cells and bioactive lipids look to create a new class of anti-cancer therapy.
France to make personalised medicine a reality?
France has placed itself firmly at the forefront of research into personalised medical solutions for cancer, infectious diseases and rare genetic diseases by investing nearly half a billion euros into the ADNA project.
Evotec focuses on drug discovery with sale of technologies division to PE
Evotec AG has sold its cell analysis instrument division, Evotech Technologies, to PerkinElmer to allow it to focus more keenly on its drug discovery pipeline and drug discovery services divisions.
Cross discipline approach could lead to tailored cancer drugs
A new cross-disciplinary collaboration could lead to cancer treatments designed specifically for individual patients.
Pfizer scraps cholesterol drug
The heart of Pfizer's business took a major blow when it was forced to halt development on their most promising cholesterol drug.
01-Dec-2006
Gene expression markets face technical hurdles
In order to achieve their expected growth, gene expression markets must overcome the technical hurdles that are currently holding them back.
| « Previous month | Next month » |
© 2000/2009 - Decision News Media SAS - All right reserved.
